OncoSec Medical (OTC:ONCS) said Wednesday lead investigator Shailender Bhatia was featured in The Journal Newspaper, a local Seattle news outlet.
biomedical company, founded in 2011, develops advance-stage
ElectroOncology anti-cancer therapies to treat people with solid
Bhatia is the principle investigator for the company’s
Phase II merkel cell carcinoma clinical trial. The skin cancer is rare
The article, titled “Fighting skin cancer with
electroimmunotherapy,” outlines the basis for OncoSec’s Phase II merkel
cell carcinoma study and describes the urgent need for a new therapy for
this patient population.
The article can be read by following
related news, the University of Washington and OncoSec were also
featured in a news segment by the Seattle NBC affiliate news agency,
OncoSec uses its electroporation delivery system which
applies cell membrane stimulation to deliver immunotherapy or
chemotherapy to treat a range of cancerous tumour types.
electroporation system has proven to enhance cellular uptake,
effectively treating cancerous cells while sparing surrounding healthy
tissue cutting through the toxic side effects of current available
treatment options like chemotherapy and radiation.
In 2011, the
company managed to outline a clinical development plan for its local and
potentially systemic ElectroImmunotherapy program, which uses the OMS
system to deliver a DNA-based immunotherapy, known as DNA IL-12.
IL-12 IS designed to induce a local immune response against the treated
cancerous tumour, while exploiting this response to initiate a global
systemic response against untreated tumours in other areas of the body.
For the metastatic melanoma trial, a total of up to 25 patients with stage three or four cutaneous and in-transit metastatic
melanoma will be enrolled in the phase two, single-arm, open-label and multi-centre study.